文献速递淋巴瘤

高级别B细胞淋巴瘤非特指型的定义与治疗

Defining and treating high-grade B-cell lymphoma, NOS.
PubMed 文献 · Blood · 2022-01-01

高级别B细胞淋巴瘤非特指型(HGBL, NOS)是新近提出的侵袭性B细胞淋巴瘤诊断类别,形态呈伯基特样或母细胞样但无双击细胞遗传学且不能归入其他明确亚型。该病罕见且异质,多数呈生发中心B细胞表型,高达45%携带单打击MYC重排。治疗因罕见和诊断不一致而缺乏标准,早期可用R-CHOP±放疗,晚期宜用强化伯基特样方案加CNS预防,但>60岁患者常不耐受强化免疫化疗。

要点

  • HGBL, NOS诊断需排除双击细胞遗传学及其他明确亚型,形态呈伯基特样或母细胞样。
  • 高达45%病例携带单打击MYC重排,多数呈生发中心B细胞表型,无统一免疫/细胞遗传学特征。
  • 晚期患者宜用强化伯基特样方案加CNS预防,>60岁常不耐受强化免疫化疗。

核心结论

  • HGBL, NOS是罕见异质的侵袭性B细胞淋巴瘤类别,治疗因罕见和诊断不一致而缺乏标准,需基于基因表达和基因组学的分类改进以开展特异性试验。

研究设计与样本

  • 综述,讨论HGBL, NOS的当前临床病理概念、预后和治疗现有数据,并基于新兴分子诊断勾勒未来分类扩展。

主要发现

  • HGBL, NOS罕见且异质,多数呈生发中心B细胞表型,高达45%携带单打击MYC重排,无其他统一免疫表型或细胞遗传学特征。
  • 基因表达谱分析显示高达15%目前分类为弥漫大B细胞淋巴瘤的肿瘤呈现HGBL样GEP特征,提示可用更客观的分子标准显著扩展HGBL类别。
  • 少数患者为早期疾病,晚期HGBL, NOS常表现为侵袭性播散性疾病、高乳酸脱氢酶和结外器官(包括中枢神经系统)受累。

关键数值与推荐

  • 早期HGBL, NOS可采用标准R-CHOP为基础方案±放疗。
  • 晚期HGBL, NOS宜采用强化伯基特淋巴瘤样方案加CNS预防。
  • 许多诊断时年龄>60岁患者不适合强化免疫化疗。

临床怎么用

  • 早期HGBL, NOS可考虑标准R-CHOP为基础方案±放疗。
  • 晚期HGBL, NOS常表现为播散性疾病、高LDH和结外受累,宜考虑强化伯基特样方案加CNS预防。
  • 对>60岁患者需评估强化免疫化疗的适用性。

局限性

  • HGBL, NOS罕见且诊断模式不一致,导致最佳治疗定义不明确。
  • 需要改进的GEP和/或基因组学病理分类以促进HGBL特异性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or blastoid morphology that do not have double-hit cytogenetics and that cannot be classified as other well-defined lymphoma subtypes. HBCLs, NOS, are rare and heterogeneous; most have germinal center B-cell phenotype, and up to 45% carry a single-hit MYC rearrangement, but otherwise, they have no unifying immunophenotypic or cytogenetic characteristics. Recent analyses using gene expression profiling (GEP) revealed that up to 15% of tumors currently classified as diffuse large B-cell lymphoma display an HGBL-like GEP signature, indicating a potential to significantly expand the HGBL category using more objective molecular criteria. Optimal treatment of HGBL, NOS, is poorly defined because of its rarity and inconsistent diagnostic patterns. A minority of patients have early-stage disease, which can be managed with standard R-CHOP-based approaches with or without radiation therapy. For advanced-stage HGBL, NOS, which often presents with aggressive disseminated disease, high lactate dehydrogenase, and involvement of extranodal organs (including the central nervous system [CNS]), intensified Burkitt lymphoma-like regimens with CNS prophylaxis may be appropriate. However, many patients diagnosed at age >60 years are not eligible for intensive immunochemotherapy. An improved GEP- and/or genomic-based pathologic classification that could facilitate HGBL-specific trials is needed to improve outcomes for all patients. In this review, we discuss the current clinicopathologic concept of HGBL, NOS, and existing data on its prognosis and treatment and delineate potential future taxonomy enrichments based on emerging molecular diagnostics.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Olszewski AJ, Kurt H, Evens AM, et al. Defining and treating high-grade B-cell lymphoma, NOS. Blood. 2022. PMID: 34525177. doi:10.1182/blood.2020008374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。